阿德福韦酯治疗对α-干扰素无应答的慢性乙型肝炎的临床观察

Adefovir dipivoxil treatment in patients with chronic hepatitis B nonresponsible to interferon-α

目的观察阿德福韦酯治疗对α-干扰素无应答的CHB患者的疗效。方法27例对α-干扰素无应答的CHB患者,口服阿德福韦酯10mg,1次/日,随访至18个月,观察肝功能、乙型肝炎病毒标记物及HBV DNA的变化情况。结果27例患者在6个月、12个月和18个月时HBV DNA阴转率分别为18.5%、29.6%和44.4%;ALT复常率分别为88.9%、92.6%和85.2%;HBeAg血清学转换率分别为7.4%、14.8%和25.9%。结论阿德福韦酯治疗对α-干扰素无应答的CHB患者的疗效随疗程的延长逐渐增加。

Objective To identify the efficacy of adefovir dipivoxil in CHB patients non-responsive to α- interferon. Methods There were twenty seven CHB patients non-responsive to α- interferon treatment. The patient orally took adefovir dipivoxil 10 mg once daily for eighteen months and we kept close investigation and research on the impact of HBV DNA , liver function tests and hepatitis B virus markers. Results In six, twelve and eighteen month treatment, the negativity rates of HBV DNA were 18.5%, 29.6 % and 44.4% ; the rates of ALT/AST returning to normal were 88.9 %, 92.6% and 85.2% and the rates of HBeAg seroconversion were 7.4%, 14.8% and 25.9%, respectively. Conclusions The efficacy of adefovir dipivoxil treatment in patients with chronic hepatitis B nonresponsible to interferon-α will increase along with the treatment period.